The State of China Biotech - Part I
Facts and Figures from ChinaBio -
Driving Factors and Government Programs
125 views
00:10:43 - Uploaded by Song Essinova, LLC on February 18, 2009
There has been much debate on the state of new drug development in China. Are there novel molecules being discovered there? What is the level of clinical trial activity? Are VCs investing in China? What about M&A and IPOs?
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference.
In this segment, Mr. Scott highlights 10 driving factors behind China's biopharmaceutical industry, and specifically the major government programs as one of the key factors.
Tags: China, ChinaBio, Greg Scott, China biotech, MOST, Ministry of Science and Technology, MOH, Ministry of Health, Zhangjiang Hi-Tech Park, Zhongguancun Life Science Park, BioBay, TEDA, Chine Academy of Sciences, CAS, China Academy of Medical Sciences, CAMS,
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Business & Finance
-
Stan Yakatan Views on the Biotech Industry
-
The Matchmaker for the pharmaceutical industry
-
The State of China Biotech 2010 - Part I
-
The State of China Biotech 2010 - Part II
-
The State of China Biotech 2010 - Part III
-
ChinaBio Accelerator
-
The State of China Biotech - Part I
-
The State of China Biotech - Part II
-
The State of China Biotech - Part III
